An ongoing dialogue on HIV/AIDS, infectious diseases,
November 22nd, 2008
“Salvage” Rx for HIV: Macro Good News, Micro Bad News
I’ve written before how the number of treatment experienced patients who have no options for successful therapy has dwindled to a tiny — but unfortunate — few. Darunavir, maraviroc, raltegravir, and etravirine (in order of FDA approval) are that good.
Two presentations at recent scientific meetings confirmed the staggering efficacy of these newer drugs. Notably, both described response rates that exceeded what was reported in pivotal phase III studies — telling us that if anything, results in clinical practice will be better than in the trials, likely because a broader range of drugs is now available to the prescribing clinician. (By contrast, patients in the MOTIVATE studies of maraviroc couldn’t use darunavir — not yet approved.)
First, this summer at the IAC meeting in Mexico City, a French group described a 90% virologic suppression rate (< 50 at 24 weeks) for 103 patients with triple class resistance receiving raltegravir, etravirine, and darunavir (sometimes with other agents). Second, more recently at ICAAC, a group from Kaiser Permanente reported that 50 out of 53 patients in their etravirine expanded access program were virologically suppressed — many of whom did not even have full susceptibility to darunavir or etravirine.
Wow.
Which brings me to an e-mail I received this week which included the following chilling piece of information:
He has rather resistant virus, and has been on Truvada, Darunavir, Ritonavir, and Raltegravir. His most recent viral loads were 450 then 920 …
Needless to say, my response included a comment that the rising viral load on a raltegravir-based regimen was “worrisome”.
In addition, a patient who is a typical raltegravir success story from our practice — high-level triple class resistance, never previously virologically suppressed, but HIV RNA undetectable for now 2-plus years — had a viral load come back recently at nearly a thousand. (He says he had a cold.) Confirmation of this result is pending (I like to wait at least a couple of weeks before repeating these) so of course this could just be a mega-blip, but needless to say I’m worried about him too.
With the disappointing news on bevirimat presented at ICAAC — showing that some 40% of individuals harbor a polymorphism in the gag region of HIV that makes their viruses essentially resistant to the drug — we don’t really have promising drugs in the pipeline for this group of individuals, however small that group may be.
Let’s hope this precarious state of affairs is a temporary one.
Paul E. Sax, MD
Associate Editor
NEJM Clinician
Biography | Disclosures & Summaries
Learn more about HIV and ID Observations.
FROM NEJM — Recent Infectious Disease Articles- Oya Virus in a Patient with Severe Hepatitis, Enteritis, and Coagulopathy September 24, 2026Oya virus, an orthobunyavirus, was identified in a 54-year-old woman who had sepsis-like symptoms, including leukocytosis, thrombocytopenia, elevated liver-function values, and disseminated intravascular coagulation.
- Cerebral Schistosomiasis September 24, 2026A rice farmer presented to the ED after a 1-minute episode of arm and leg shaking on the right side. MRI showed linear enhancement associated with a cluster of enhancing nodules and surrounding edema in the left frontal lobe.
- The End of the War on Biomedical Science? September 24, 2026The turmoil of the past 20 months has inflicted lasting damage on American science and public health. But history and recent events suggest that the attacks will subside.
- Human Adenovirus B3–Induced Immune Thrombocytopenia and Thrombosis September 17, 2026Virus-induced immune thrombocytopenia and thrombosis after HAdV-B3 infection supports a shared platelet factor 4–targeted immune mechanism linking natural adenovirus infection and adenoviral vector–associated disease.
- Honoring the Legacy of the HIV Epidemic September 17, 2026Progress against the U.S. HIV epidemic is stalling, owing in part to government attacks and fear. But clinicians, patients, and activists can learn from the epidemic’s early heroes and find ways to advance.
- Oya Virus in a Patient with Severe Hepatitis, Enteritis, and Coagulopathy September 24, 2026